Best Cytokine Signalling Forum Podcasts (2025)

1
Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025 28:57

Play Pause

5d ago28:57

28:57

Join Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.…

1
Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025 45:23

19d ago45:23

45:23

Join Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer from the German Rheumatology Research Center in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigat…

1
Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials 17:45

26d ago17:45

17:45

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.…

1
Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting 13:24

1M ago13:24

13:24

Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’…

1
Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA 16:44

2M ago16:44

16:44

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered treatment outcomes in European real-world patients with axSpA and PsA, treated with secukinumab and the effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with a…

1
Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash 41:27

2M ago41:27

41:27

Join Professor Iain McInnes from the University of Glasgow, and Professor Peter Nash from the Griffith University in Brisbane, as they discuss the concept of difficult-to-treat disease in rheumatology.By The Immune-Mediated Inflammatory Disease Forum

1
EULAR 2025 Review Podcast 1:05:19

2M ago1:05:19

1:05:19

Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they review their highlights of the recent EULAR 2025 congress, and watch them discuss the key abstracts and information.By The Immune-Mediated Inflammatory Disease Forum

1
Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment 15:20

2M ago15:20

15:20

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss three papers: the impact of TOF treatment on weight and BMI in RA patients, to that of alternate treatment options for RA patients with prior MTX-i…

1
EULAR 2025 Highlights: Day 4 3:25

3M ago3:25

3:25

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 4 of EULAR 2025 (Saturday, June 14).By The Immune-Mediated Inflammatory Disease Forum

1
EULAR 2025 Highlights: Day 3 2:36

3M ago2:36

2:36

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 3 of EULAR 2025 (Friday, June 13).By The Immune-Mediated Inflammatory Disease Forum

1
Discussing PsA: Real-world data on biologic switching and the development of EMMs 23:11

3M ago23:11

23:11

Join Professors Philip Mease and Laura Coates and as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on biologic switching for the treatment of PsA using real-world data as well as the development of extramusculoskeletal manifestations in PsA and axSpA patients treated with upadacitinib.…

1
EULAR 2025 Highlights: Day 2 4:39

3M ago4:39

4:39

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 2 of EULAR 2025 (Thursday, June 12).By The Immune-Mediated Inflammatory Disease Forum

1
EULAR 2025 Highlights: Day 1 4:03

3M ago4:03

4:03

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 1 of EULAR 2025 (Wednesday, June 11).By The Immune-Mediated Inflammatory Disease Forum

1
EULAR 2025 Preview Podcast 25:23

3M ago25:23

25:23

Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they guide you through what they are most looking forward to in RA, PsA, and axSpA at EULAR 2025, so that you can better plan your time at what will be a busy and exciting congress.By The Immune-Mediated Inflammatory Disease Forum

1
Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA 10:25

3M ago10:25

10:25

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE in patients with RA treated with JAKis compared to bDMARDs from the “JAK-pot” study, and the efficacy and safety of zimlovisertib, ritlecitinib and …

1
Podcast: AuToDeCRA, June 2025 30:26

3M ago30:26

30:26

Join Professor Ian McInnes from the University of Glasgow, and Professors John Isaacs and Andrew Cope, as they discuss the latest AuToDeCRA study and what this means for rheumatology.By The Immune-Mediated Inflammatory Disease Forum

1
Webinar Highlights Podcast: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs 23:13

3M ago23:13

23:13

Join Professor Herve Bachelez and Professors Iain McInnes and Tim Orchard as they discuss the recent webinar hosted on the IMID Forum: “Advancing Patient Care Through an Interdisciplinary Approach to IMIDs”. Watch them discuss key highlights from the webinar including the clinical pathogenetic pathways, the Rheum-Derm-Gastro triggers and its implic…

1
Author Interview: Dr Saqr Alsakarneh, May 2025 26:08

3M ago26:08

26:08

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Saqr Alsakarneh, Internal Medicine Resident at University of Missouri–Kansas City in the US, as they discuss ‘Risk of De Novo Inflammatory Bowel Disease in Patients with Psoriasis and Psoriatic Arthritis Treated with IL-17A Inhibitors: A Population-Based Study’.…

1
Discussing axSpA: JAKi cycling and long-term safety of bimekizumab in patients with axSpA or PsA 32:17

4M ago32:17

32:17

Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA.In this episode, our faculty discusses two papers: the first assesses switching to secukinumab or cyc…

1
Discussing RA: MACE, VTE, and malignancy in filgotinib RA and UC patients, and MACE related to JAKis 8:31

4M ago8:31

8:31

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-T…

1
Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA 32:21

5M ago32:21

32:21

Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

1
Discussing PsA: JAKi Comparative safety & Burden and determinants of multi‑b/tsDMARD failure in PsA 29:23

5M ago29:23

29:23

Join Professors Laura Coates and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis. They also give insights into th…

1
Discussing RA: Pain reduction & choosing second-line DMARDs after unresponsive first-line DMARDs 21:40

5M ago21:40

21:40

Join Professors Iain McInnes and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers: effectiveness of JAKi compared with bDMARDs on pain reduction and effective second‑line b/tsDMARD for patients with rheumatoid arthritis unrespon…

1
Author Interview: Professor Phillip Helliwell, March 2025 22:30

6M ago22:30

22:30

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Phillip Helliwell, Professor of rheumatology at The University of Leeds in the UK, as they discuss ‘Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study’By The Immune-Mediated Inflammatory Disease Forum

1
Author Interview: Professor Phillip Helliwell, 2025 26:36

6M ago26:36

26:36

Author Interview: Professor Phillip Helliwell, 2025 by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

1
Discussing PsA: Bimekizumab improves patient-reported outcomes and work productivity 32:04

6M ago32:04

32:04

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate…

1
Discussing RA: Baricitinib dose reduction and switching to bDMARDs vs JAKis 11:17

6M ago11:17

11:17

Join Professors Iain McInnes, Hans Bijlsma, and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers: baricitinib dose reduction in patients with RA achieving sustained disease control and switching to bDMARDs vs cycling among JAKis…

1
Discussing axSpA: Long-term safety and efficacy of Bimekizumab results from BE-AGILE & BE-MOBILE 1/2 25:05

6M ago25:05

25:05

Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA.In this episode, our faculty discusses two papers both focusing on the long-term safety and efficacy …

1
Author Interview: Professor Denis McGonagle, 2025 36:01

7M ago36:01

36:01

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Denis McGonagle, Professor of investigative rheumatology at the NIHR funded Academic Unit for the Musculoskeletal Diseases and Leeds Teaching Hospitals NHS Trust in the UK, as they discuss his recent review ‘Subclinical psoriatic arthritis and disease interception—whe…

1
Discussing RA: Insights into sustained DMARD-free remission and barriers to CAR T-cell therapy 11:18

7M ago11:18

11:18

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, Professor McInnes discusses two papers: subgroups of patients with early RA with or without bDMARD who reached sustained DMARD-free remission and barriers to the widespread adoption of C…

1
Discussing AxSpA Podcast: Efficacy and Safety of Upadacitinib 18:42

9M ago18:42

18:42

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.…

1
Discussing RA: Insights into Filgotinib and Tofacitinib in RA 24:13

9M ago24:13

24:13

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid a…

1
ACR 2024 Review Podcast 50:04

9M ago50:04

50:04

ACR 2024 Review Podcast by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

1
Discussing PsA: DISCOVER-2 and BE OPTIMAL/BE COMPLETE post-hoc analyses 30:53

9M ago30:53

30:53

Join Professors Peter Nash and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a post hoc analysis examining the rapid and sustained efficacy of bimekizumab in PsA patients across different subgroups, focusing on improvements in pain, fatigue, and physical function over 16 weeks. The conve…

1
Discussing RA: Insights into Filgotinib and Tofacitinib in RA 19:16

10M ago19:16

19:16

Join Professor Iain McInnes and Professor Johannes Bijlsma for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitin…

1
Webinar Highlights Podcast: CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases 26:39

10M ago26:39

26:39

Webinar Highlights Podcast: Join Professor Iain McInnes and Professor Georg Schett as they discuss the recent webinar hosted on the IMID Forum: “CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases”. Listen to them discuss key highlights from the webinar including the development of CAR T-cell therapy, the application of CAR T to autoimmu…

1
ACR 2024 Highlights: Day 3 4:21

10M ago4:21

4:21

ACR 2024 Highlights: Day 3 by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

1
ACR 2024 Highlights: Day 2 3:36

10M ago3:36

3:36

ACR 2024 Highlights: Day 2 by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

1
ACR 2024 Highlights: Day 1 2:55

10M ago2:55

2:55

ACR 2024 Highlights: Day 1 by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

1
ACR 2024: Preview Podcast 19:51

10M ago19:51

19:51

ACR 2024: Preview Podcast by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

1
AxSpA Podcast: Efficacy and Safety of IV secukinumab 23:30

10M ago23:30

23:30

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, and Atul Deodhar to discuss a recent study on the efficacy and safety of IV secukinumab in patient with active axSpA.By The Immune-Mediated Inflammatory Disease Forum

1
Discussing RA: Navigating JAKis, TNFis, and the quest for optimal RA therapy 22:03

10M ago22:03

22:03

Join Professor Iain McInnes and Professor Leonard Calabrese for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the efficacy and safety of JAK inhibitors and TNF inhibitors for rheumatoid arthritis, while also u…

1
Author Interview: Derin Karacabeyli, 2024 33:27

11M ago33:27

33:27

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Derin Karacabeyli of Arthritis Research Canada, a rheumatologist and resident in the University of British Columbia Clinician Investigator Program, as they discuss his recent paper ‘Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agon…

1
Webinar Highlights Podcast 2: Evolving Therapeutic Strategies for Psoriatic Diseases 32:56

11M ago32:56

32:56

Webinar Highlights Podcast: Join Professor Christopher Ritchlin, and Professor Philip Mease as they discuss the recent webinar hosted on the IMID Forum ‘Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2’. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the sim…

1
PsA Podcast: Bimekizumab: Efficacy, safety, and effectiveness in PsA 21:04

11M ago21:04

21:04

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a matching-adjusted indirect comparison (MAIC) to assess the comparative efficacy of bimekizumab and risankizumab in patients with psoriatic arthritis over 52 weeks, and a post hoc analysis invest…

1
Discussing RA: Long-term safety and efficacy of upadacitinib in SELECT trials 19:24

12M ago19:24

19:24

Join Professor Iain McInnes and Professors Hideto Kameda and Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the long-term efficacy and safety of upadacitinib in the SELECT trials.…

1
Discussing AxSpA: Incidence of uveitis following bimekizumab treatment 24:11

1y ago24:11

24:11

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.…

1
Author Interview: Professor Laura Andreoli, 2024 44:09

1y ago44:09

44:09

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Laura Andreoli, a Professor of Rheumatology at the University of Brescia, as they discuss her recent paper ‘The outcomes of children born to mothers with autoimmune rheumatic diseases’, published in The Lancet. Rheumatology on 11th June 2024.…

1
Discussing RA: Neutrophil-to-lymphocyte ratio and treatment response to filgotinib 16:05

1y ago16:05

16:05

Join Professor Iain McInnes and Professors Hideto Kameda and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss a paper that investigated whether the baseline neutrophil-to-lymphocyte ratio had an effect on the treatment respons…

1
Discussing PsA: Guselkumab and analysis of genetic markers 25:46

1y ago25:46

25:46

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered the post hoc analysis of PsA patients receiving guselkumab, focusing on disease control across domains and patient characteristics, and a systematic review and meta-analysis on genetic markers and…